TrueBinding Inc. is at the forefront of developing novel monoclonal antibody therapeutics aimed at addressing significant unmet medical needs in various fields, including neurodegenerative and metabolic diseases, stroke, and oncology. Their lead candidate, TB006, is a humanized monoclonal antibody specifically designed to target Galectin-3, a protein implicated in the progression of Alzheimer’s Disease. By inhibiting Galectin-3, TB006 aims to disrupt the formation of toxic amyloid beta plaques in the brain, which are responsible for cognitive decline in Alzheimer's patients. Pre-clinical studies have shown promising results, indicating that TB006 can significantly reduce these plaques and improve cognitive function, thereby offering hope for more effective treatments in the realm of precision medicine.

In addition to their therapeutic development, TrueBinding also provides contract development and manufacturing services to the biopharmaceutical industry, enhancing the efficiency and speed of monoclonal antibody production. Their commitment to innovation is further exemplified by their Expanded Access Program for TB006, which allows patients with Alzheimer's Disease to access investigational treatments outside of traditional clinical trials. TrueBinding's focus on clinical trials underscores their dedication to advancing medical science and improving patient outcomes, particularly for conditions like Autism Spectrum Disorder and Parkinson’s Disease, where they are actively exploring new therapeutic avenues.

United States

Founded in 2016, TrueBinding Inc. is a clinical-stage biotherapeutic company researching and developing first-in-class monoclonal antibody drugs to treat Dementia and Alzheimer's Disease (AD).

TrueBinding

Company Details